-
公开(公告)号:US20220193072A1
公开(公告)日:2022-06-23
申请号:US17548842
申请日:2021-12-13
Applicant: Arvinas Operations, Inc.
Inventor: Xin CHEN , Andrew P. CREW , John FLANAGAN , Sheryl Maxine GOUGH , Royal J. HASKELL, III , Marcia Dougan MOORE , Yimin QIAN , Ian Charles Anthony TAYLOR , Jing WANG
IPC: A61K31/497 , A61P35/04 , A61K31/519
Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.
-
公开(公告)号:US20250120968A1
公开(公告)日:2025-04-17
申请号:US18988049
申请日:2024-12-19
Applicant: Arvinas Operations, Inc.
Inventor: Xin CHEN , Andrew P. CREW , John FLANAGAN , Sheryl Maxine GOUGH , Royal J. HASKELL, III , Marcia Dougan MOORE , Yimin QIAN , Ian Charles Anthony TAYLOR , Jing WANG
IPC: A61K31/496 , A61K31/519 , A61K47/02 , A61K47/22 , A61K47/26 , A61K47/38 , A61P35/00
Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.
-
公开(公告)号:US20240066032A1
公开(公告)日:2024-02-29
申请号:US18489262
申请日:2023-10-18
Applicant: Arvinas Operations, Inc.
Inventor: Sarah Deborah CHIRNOMAS , Richard Walter GEDRICH , Ronald PECK , Ian Charles Anthony TAYLOR
IPC: A61K31/506 , A61K9/00 , A61K31/496 , A61K31/501 , A61K31/58 , A61P35/00
CPC classification number: A61K31/506 , A61K9/0053 , A61K31/496 , A61K31/501 , A61K31/58 , A61P35/00
Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I),
or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.-
公开(公告)号:US20220184078A1
公开(公告)日:2022-06-16
申请号:US17548161
申请日:2021-12-10
Applicant: Arvinas Operations, Inc.
Inventor: Sarah Deborah CHIRNOMAS , Richard Walter GEDRICH , Ronald PECK , Ian Charles Anthony TAYLOR
IPC: A61K31/506 , A61K9/00 , A61K31/58 , A61P35/00 , A61K31/496 , A61K31/501
Abstract: The present application relates to treating and/or preventing prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in a subject in need of treatment having particular somatic AR tumor biomarker status, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, X1, X2, X3, X4, and n are defined herein.
-
公开(公告)号:US20210060008A1
公开(公告)日:2021-03-04
申请号:US17001519
申请日:2020-08-24
Applicant: Arvinas Operations, Inc.
Inventor: Xin CHEN , Andrew P. CREW , John FLANAGAN , Sheryl Maxine GOUGH , Royal J. HASKELL, III , Marcia Dougan MOORE , Yimin QIAN , Ian Charles Anthony TAYLOR , Jing WANG
IPC: A61K31/496 , A61K47/38 , A61K47/26 , A61K47/02 , A61K47/22 , A61K31/519 , A61P35/00
Abstract: The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.
-
-
-
-